ALA Insider Trading

Insider Ownership Percentage: 17.75%
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Arovella Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Arovella Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Arovella Therapeutics Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 11/16/2021 10:05 AM ET

This chart shows the closing price history over time for ALA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Yours Free! Top FIVE Dividend Stocks Right Now
This Ultimate Dividend Package contains an "A"-rated, ultra-safe dividend stock with a huge 8% yield, and one income expert's No. 1 dividend stock for a LIFETIME of income. 

Click here to get your FREE Ultimate Dividend Package.

Arovella Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/5/2023Elizabeth StonerInsiderIssued500,000A$0.02A$10,000.00
12/15/2022David SimmondsInsiderIssued1,600,000A$0.03A$40,000.00
12/2/2022Michael BakerInsiderIssued1,586,842A$0.04A$60,300.00
3/16/2022Paul HopperInsiderIssued631,578A$0.04A$23,999.96
12/16/2021Paul HopperInsiderIssued6,000,000A$0.04A$240,000.00
11/11/2021Michael BakerInsiderIssued8,000,000A$0.04A$328,000.00
See Full Table

SEC Filings (Institutional Ownership Changes) for Arovella Therapeutics (ASX:ALA)

11.00% of Arovella Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat short-term insomnia, which is marketed under the brand name of Ambien or Stilnox; invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer; OroMist, an oro-mucosal technology that delivers a range of drug classes through the cheeks, gums, tongue, or floor of the mouth; and Anagrelide to treat cancer. The company also develops oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Read More on Arovella Therapeutics

Today's Range

Now: N/A

50 Day Range


52 Week Range

Now: N/A



Average Volume


Market Capitalization


P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Arovella Therapeutics?

Arovella Therapeutics' top insider shareholders include:
  1. David Simmonds (Insider)
  2. Elizabeth Stoner (Insider)
  3. Michael Baker (Insider)
  4. Paul Hopper (Insider)
Learn More about top insider investors at Arovella Therapeutics.
No Matter The Market, Options Trading Could Earn You More
There’s no way to predict Wall Street’s future, but by using options trading, you have the opportunity to take advantage of any trend. Expert Wendy Kirkland explains how in her latest free guide.
Download it for free here!